Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study.

被引：0
作者：
Luminari, Stefano
Harnett, James
Thieblemont, Catherine
Prochazka, Katharina
Townsend, William
Radford, John
Serna, Angel
Jalbert, Jessica J.
Kamat, Siddhesh
Wang, Joy
Ambati, Srikanth R.
Mohamed, Hesham
Chaudhry, Aafia
Sanz, Hector
Hermans, Ruben
Maissenhaelter, Benedikt
Hampp, Christian
Bachy, Emmanuel
机构：
[1] Azienda Unita Sanit Locale RCCS Reggio Emilia, Hematol Unit, Reggio Emilia, Italy
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Univ Paris Cite, Paris, France
[4] Hop St Louis, Assistance Publ Hop Paris, Hematooncol, Paris, France
[5] Med Univ Graz, Dept Clin Hematol, Univ Clin Internal Med, Graz, Austria
[6] Univ Coll London Hosp, Canc Res UK, London, England
[7] Univ Coll London Hosp, UCL Canc, London, England
[8] Univ Manchester, Manchester, England
[9] Manchester Acad Hlth Sci Ctr, Christie NHS Fdn Trust, Manchester, England
[10] Vall dHebron Hosp Univ, Dept Hematol, Barcelona, Spain
[11] IQVIA, Barcelona, Spain
[12] IQVIA, London, England
[13] IQVIA, Munich, Germany
[14] Hosp Civils Lyon, Dept Hematol, Lyon, France
[15] Univ Claude Bernard Lyon 1, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7076
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
    Fitzgerald, Lindsey
    Kittai, Adam
    Nastoupil, Loretta J.
    Waller, Alexandra
    Jacobson, Caron A.
    Saucier, Anna
    Kamdar, Manali K.
    Spradley, Janet
    Denlinger, Nathan
    Chipman, Jonathan
    Hu, Boyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2 nd Line CAR T Therapy
    Schneider, Michael
    Chong, Elise A.
    Barta, Stefan K.
    Nasta, Sunita D.
    Svoboda, Jakub
    Carter, Jordan
    Cook, Michael Roderick
    Hossain, Nasheed
    Schuster, Stephen J.
    Difilippo, Heather
    Plastaras, John P.
    Lariviere, Michael
    Ruella, Marco
    Porter, David L.
    Frey, Noelle
    Landsburg, Daniel J.
    BLOOD, 2024, 144 : 5123 - 5124
  • [43] Comparison of Clinical Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel in the Elara Trial Versus a Real-World External Control Arm of Patients Treated with Standard of Care
    Hao, Yanni
    Hsu, Wei-Chun
    Parzynski, Craig S.
    Bodoni, C. Lobetti
    Degtyarev, Evgeny
    Hampson, Lisa
    Masood, Aisha
    Wu, Wen-Hsing
    BLOOD, 2021, 138
  • [44] Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
    Yi, Jun Ho
    Kim, Seok Jin
    Yoon, Dok Hyun
    Suh, Cheolwon
    Chang, Myung Hee
    Yang, Deok Hwan
    Jo, Jae-Cheol
    Hyun, Shin Young
    Eom, Hyeon-Seok
    Lee, Jeong-Ok
    Kwon, Ji Hyun
    Han, Sang Hoon
    Lee, Seung-Shin
    Kwak, Jae-Yong
    Kim, Se Hyung
    Kim, Dae Sik
    Lee, Ji Hyun
    Oh, Sung Yong
    Ryoo, Hun Mo
    Kim, Hyo Jung
    Kim, Won Seog
    CANCER COMMUNICATIONS, 2021, 41 (03) : 275 - 278
  • [45] Rituximab (R) in combination with fludarabine (F) and cyclophosphamide (C) in relapsed follicular lymphoma (FL) patients (pts). Final results of FC plus R phase II trial by the GISL.
    Sacchi, Stefano
    Pozzi, Samantha
    Marcheselli, Raffaella
    Luminari, Stefano
    Federico, Massimo
    Tucci, Alessandra
    Merli, Francesco
    Orsucci, Loretta
    Cervetti, Giulia
    Occhini, Ubaldo
    Liberati, Marina
    Callea, Vincenzo
    Brugiatelli, Maura
    Baldini, Luca
    BLOOD, 2006, 108 (11) : 782A - 782A
  • [46] EFFICACY AND SAFETY OF BORTEZOMIB-RITUXIMAB (VCR) VS RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED, R-NAIVE/-SENSITIVE FOLLICULAR LYMPHOMA (FL): OUTCOME ACCORDING TO PRIOR THERAPY
    Crump, M.
    Scheliga, A.
    Mayer, J.
    Offner, F.
    Teixeira, A.
    Kuliczkowski, K.
    Liberati, A. M.
    Okada, C. Y.
    Esseltine, D. L.
    Enny, C.
    Zhu, E.
    Van de Velde, H.
    Elsayed, Y. A.
    Coiffier, B.
    ANNALS OF ONCOLOGY, 2011, 22 : 186 - 186
  • [47] Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example
    Iacoboni, Gloria
    Raya, Maria Perez
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 11 - 16
  • [48] Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib plus Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial
    Trotman, Judith
    Zinzani, Pier Luigi
    Song, Yuqin
    Delarue, Richard
    Barnes, Gisoo
    Kim, Pil
    Ivanova, Elena
    Tang, Boxiong
    Mayer, Jiri
    De Oliveira, Ana C.
    Assouline, Sarit
    Flowers, Christopher R.
    BLOOD, 2023, 142
  • [49] Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
    Locke, Frederick L.
    Hu, Zhen-Huan
    Siddiqi, Tanya
    Jacobson, Caron A.
    Nikiforow, Sarah
    Ahmed, Sairah
    Miklos, David B.
    Lin, Yi
    Lunning, Matthew A.
    Hill, Brian T.
    Ghobadi, Armin
    Miao, Harry
    Shahani, Shilpa
    Spooner, Clare
    Fu, Christine
    Patel, Anik R.
    Xu, Hairong
    Pasquini, Marcelo C.
    BLOOD, 2022, 140 : 7512 - 7515
  • [50] Durable Efficacy and Manageable Safety in Patients Aged ≥75 Years With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Treated With Tisagenlecleucel in the Real-World Setting
    Landsburg, Daniel J.
    Heim, Michael
    Moskop, Amy
    Foley, Stephen Ronan
    Hill, Brian T.
    Schofield, Grant
    Jacobson, Caron A.
    Jaglowski, Samantha
    Locke, Frederick L.
    Ram, Ron
    Riedell, Peter A.
    Shah, Gunjan L.
    Popplewell, Leslie L.
    Tiwari, Ranjan
    Lim, Stephen
    Maier, Harald
    Majdan, Marta
    Pasquini, Marcelo C.
    Frigault, Matthew J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S471 - S471
12345